Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer
This Protocol is a Randomized Prospective Study Comparing Prophylactic and on Demand Sildenafil Citrate Usage Administered During and After Radiotherapy With or Without Hormone Therapy Versus Radiotherapy With or Without Hormone Therapy Alone for the Preservation of Erectile Function After Therapy for Potent Patients With Clinically Localized Prostate Cancer
Sponsor: Beth Israel Medical Center
This PHASE3 trial investigates Erectile Dysfunction and Prostate Cancer and is currently completed. Beth Israel Medical Center leads this study, which shows 9 recorded versions since 2005 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Nov 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Nov 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Feb 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beth Israel Medical Center
- Icahn School of Medicine at Mount Sinai
- Memorial Sloan Kettering Cancer Center
- St. Luke's-Roosevelt Hospital Center
For direct contact, visit the study record on ClinicalTrials.gov .